Provectus reports fully diluted shares of 528.7M as of Sep 7, 2021, down from 563.9M in 2017

PROVECTUS BIOPHARMACEUTICALS, INC.

Fully diluted shares outstanding as of Sep 7, 2021: 528,667,356 vs 563,911,848 in 2017.
Common shares outstanding: 416,575,669; warrants: 512,500; options: 4,800,000; Series D/D-1 conversion shares: 106,779,187.
All Private Warrants expired by Oct 31, 2020; Listed Warrants expired Jun 23, 2020.
Convertible notes ($30.56M) converted into Series D/D-1 Preferred on Jun 20, 2021, convertible into ~106.8M common shares.
Remaining Series B Preferred converted Aug 25, 2021; 13.35M Ratchet Warrants exercised, 68.7M expired by Aug 30, 2021.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.